An Overview of the Deadly Effects of Anabolic-Androgenic Steroids: Clinical Cases and Scientific Insights
DOI:
https://doi.org/10.12775/QS.2025.37.57251Keywords
Androgenic-anabolic steroids, Androgenic-anabolic steroids abuse, premature mortality, health consequences of AASAbstract
Background: Anabolic-androgenic steroids (AAS) are widely used for performance enhancement, but their misuse, particularly in bodybuilding and professional sports, poses significant health risks. While AAS have legitimate medical applications in treating certain hormonal disorders, abuse of these substances can lead to severe and often irreversible health consequences.
Objective: The aim of this work was to highlight the health and life risks associated with AAS abuse, with a focus on the most common causes of death, based on example case reports and scientific studies.
Materials and Methods: This review was based on scientific research and case reports obtained from the PubMed database using the following key terms: “androgenic anabolic steroids,” “androgenic anabolic steroids abuse,” and combinations of these with terms such as “premature death,” “sudden cardiac death,” “suicide,” “liver injury,” “renal failure,” and “health consequences.”
Conclusion: AAS misuse can increase the risk of sudden cardiac death, stroke, suicide and other complications. Clinical research stresses the importance of awareness, education, and medical supervision to prevent these risks, emphasizing the need for regulation and informed decision-making to protect individuals from harm.
References
1. Ganesan K, Rahman S, Zito PM. Anabolic Steroids. 2023 May 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 29494025.
2. Bond P, Smit DL, de Ronde W. Anabolic-androgenic steroids: How do they work and what are the risks? Front Endocrinol (Lausanne). 2022 Dec 19 ;13:1059473. doi: 10.3389/fendo.2022.1059473. PMID: 36644692; PMCID: PMC9837614.
3. Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014 May;24(5):383-98. doi: 10.1016/j.annepidem.2014.01.009. Epub 2014 Jan 30. PMID: 24582699.
4. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008 Jun;154(3):502-21. doi: 10.1038/bjp.2008.165. PMID: 18500378; PMCID: PMC2439524.
5. Rahnema CD, Crosnoe LE, Kim ED. Designer steroids - over-the-counter supplements and their androgenic component: review of an increasing problem. Andrology. 2015 Mar;3(2):150-5. doi: 10.1111/andr.307. Epub 2015 Feb 13. PMID: 25684733.
6. Alsaeed I, Alabkal JR. Usage and perceptions of anabolic-androgenic steroids among male fitness centre attendees in Kuwait--a cross-sectional study. Subst Abuse Treat Prev Policy. 2015 Aug 22;10:33. doi: 10.1186/s13011-015-0030-5. PMID: 26296560; PMCID: PMC4546264.
7. Kicman AT, Gower DB. Anabolic steroids in sport: biochemical, clinical and analytical perspectives. Ann Clin Biochem. 2003 Jul;40(Pt 4):321-56. doi: 10.1258/000456303766476977. Erratum in: Ann Clin Biochem. 2003 Nov;40(6):704. PMID: 12880534.
8. Smit DL, Buijs MM, de Hon O, den Heijer M, de Ronde W. Positive and negative side effects of androgen abuse. The HAARLEM study: A one-year prospective cohort study in 100 men. Scand J Med Sci Sports. 2021 Feb;31(2):427-438. doi: 10.1111/sms.13843. Epub 2020 Nov 4. PMID: 33038020.
9. Carrasquillo R, Chu K, Ramasamy R. Novel Therapy for Male Hypogonadism. Curr Urol Rep. 2018 Jun 9;19(8):63. doi: 10.1007/s11934-018-0816-x. PMID: 29886559.
10. Ranke MB, Bierich JR. Treatment of growth hormone deficiency. Clin Endocrinol Metab. 1986 Aug;15(3):495-510. doi: 10.1016/s0300-595x(86)80008-1. PMID: 2429792.
11. Davis SR. The therapeutic use of androgens in women. J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):177-84. doi: 10.1016/s0960-0760(99)00054-0. PMID: 10418991.
12. Penteado SR, Fonseca AM, Bagnoli VR, Abdo CH, Júnior JM, Baracat EC. Effects of the addition of methyltestosterone to combined hormone therapy with estrogens and progestogens on sexual energy and on orgasm in postmenopausal women. Climacteric. 2008 Feb;11(1):17-25. doi: 10.1080/13697130701741932. PMID: 18202961.
13. Ness RB, Albano JD, McTiernan A, Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med. 2009 Jan 12;169(1):41-6. doi: 10.1001/archinternmed.2008.507. PMID: 19139322.
14. Li H, Guo Y, Yang Z, Roy M, Guo Q. The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis. Burns. 2016 Jun;42(4):717-27. doi: 10.1016/j.burns.2015.08.023. Epub 2015 Oct 9. PMID: 26454425.
15. Nieschlag E. Clinical trials in male hormonal contraception. Contraception. 2010 Nov;82(5):457-70. doi: 10.1016/j.contraception.2010.03.020. Epub 2010 May 15. PMID: 20933120.
16. Wang C, Meriggiola MC, Behre HM, Page ST. Hormonal male contraception. Andrology. 2024 Oct;12(7):1551-1557. doi: 10.1111/andr.13699. Epub 2024 Jul 17. PMID: 39016284.
17. Bunin DI, Kim K, Parman T, Gahagen J, Zelinski MB, Adevai T, Wang C, Tang L, Iyer L, Endsley A, Blithe DL, Lee MS. Evaluation of dimethandrolone undecanoate in non-human primates as a candidate for long-acting injectable male contraceptive. Andrology. 2024 Dec 8. doi: 10.1111/andr.13819. Epub ahead of print. PMID: 39648590.
18. Page ST. Synthetic androgens for male contraception. Contraception. 2024 Nov 6:110735. doi: 10.1016/j.contraception.2024.110735. Epub ahead of print. PMID: 39515746.
19. Horwitz H, Andersen JT, Dalhoff KP. Health consequences of androgenic anabolic steroid use. J Intern Med. 2019 Mar;285(3):333-340. doi: 10.1111/joim.12850. Epub 2018 Nov 20. PMID: 30460728.
20. Skrzypiec-Spring M, Pokrywka A, Bombała W, Berezovska D, Rozmus J, Brawańska K, Nowicki K, Abu Faraj G, Rynkowski M, Szeląg A. Illegal Use of Testosterone and Other Anabolic-Androgenic Steroids in the Population of Amateur Athletes in Wrocław, Poland-An Unfavorable Lifestyle Trend in the Population of Men of Reproductive Age. J Clin Med. 2024 Jun 26;13(13):3719. doi: 10.3390/jcm13133719. PMID: 38999285; PMCID: PMC11242149.
21. Nieschlag E, Vorona E. MECHANISMS IN ENDOCRINOLOGY: Medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. Eur J Endocrinol. 2015 Aug;173(2):R47-58. doi: 10.1530/EJE-15-0080. Epub 2015 Mar 24. PMID: 25805894.
22. Baker JS, Graham MR, Davies B. Steroid and prescription medicine abuse in the health and fitness community: A regional study. Eur J Intern Med. 2006 Nov;17(7):479-84. doi: 10.1016/j.ejim.2006.04.010. PMID: 17098591.
23. Thiblin I, Garmo H, Garle M, Holmberg L, Byberg L, Michaëlsson K, Gedeborg R. Anabolic steroids and cardiovascular risk: A national population-based cohort study. Drug Alcohol Depend. 2015 Jul 1;152:87-92. doi: 10.1016/j.drugalcdep.2015.04.013. Epub 2015 May 11. PMID: 26005042.
24. Pärssinen M, Kujala U, Vartiainen E, Sarna S, Seppälä T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med. 2000 Apr;21(3):225-7. doi: 10.1055/s-2000-304. PMID: 10834358.
25. Rasmussen JJ, Schou M, Madsen PL, Selmer C, Johansen ML, Hovind P, Ulriksen PS, Faber J, Gustafsson F, Kistorp C. Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids: potential effect of suppressed natriuretic peptides in plasma? J Hypertens. 2018 Feb;36(2):277-285. doi: 10.1097/HJH.0000000000001546. PMID: 28863033.
26. Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014 Jun;35(3):341-75. doi: 10.1210/er.2013-1058. Epub 2013 Dec 17. PMID: 24423981; PMCID: PMC4026349.
27. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513-54. doi: 10.2165/00007256-200434080-00003. PMID: 15248788.
28. Ferenchick G, Schwartz D, Ball M, Schwartz K. Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters. Am J Med Sci. 1992 Feb;303(2):78-82. doi: 10.1097/00000441-199202000-00002. PMID: 1539613.
29. Poteshkina NG, Kovalevskaya EA, Krylova NS, Fettser DV. [Myocardial ischemia in patients with hypertrophic cardiomyopathy]. Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2019 Aug;27(Special Issue):671-676. Russian. doi: 10.32687/0869-866X-2019-27-si1-671-676. PMID: 31747160.
30. Jacobson JT. Arrhythmia Evaluation and Management. Cardiol Clin. 2019 Feb;37(1):55-62. doi: 10.1016/j.ccl.2018.08.005. Epub 2018 Oct 29. PMID: 30447716.
31. Torrisi M, Pennisi G, Russo I, Amico F, Esposito M, Liberto A, Cocimano G, Salerno M, Li Rosi G, Di Nunno N, Montana A. Sudden Cardiac Death in Anabolic-Androgenic Steroid Users: A Literature Review. Medicina (Kaunas). 2020 Nov 4;56(11):587. doi: 10.3390/medicina56110587. PMID: 33158202; PMCID: PMC7694262.
32. Hernández-Guerra AI, Tapia J, Menéndez-Quintanal LM, Lucena JS. Sudden cardiac death in anabolic androgenic steroids abuse: case report and literature review. Forensic Sci Res. 2019 Aug 19;4(3):267-273. doi: 10.1080/20961790.2019.1595350. PMID: 31489392; PMCID: PMC6713204.
33. Tirla A, Vesa CM, Cavalu S. Severe Cardiac and Metabolic Pathology Induced by Steroid Abuse in a Young Individual. Diagnostics (Basel). 2021 Jul 21;11(8):1313. doi: 10.3390/diagnostics11081313. PMID: 34441248; PMCID: PMC8394374.
34. Samreen F, Popal U, Qutrio Baloch ZA. Anabolic Steroid-Induced Myocardial Infarction in a Young Male. Cureus. 2021 Feb 1;13(2):e13054. doi: 10.7759/cureus.13054. PMID: 33680596; PMCID: PMC7925058.
35. Mustafa EM, Filho IJZ, Ferreira VRR, Sabino SB, Sternieri GB, Verdi LB, Queiroz COV, Sbardellini BC, Braile-Sternieri MCVB. AMI and Anabolic-Androgenic Steroids: Case Report with Systematic Review. Curr Cardiol Rev. 2021;17(5):e190721189769. doi: 10.2174/1573403X16999201231203405. PMID: 33390145; PMCID: PMC8950448.
36. Guzik A, Bushnell C. Stroke Epidemiology and Risk Factor Management. Continuum (Minneap Minn). 2017 Feb;23(1, Cerebrovascular Disease):15-39. doi: 10.1212/CON.0000000000000416. PMID: 28157742.
37. Graham MR, Grace FM, Boobier W, Hullin D, Kicman A, Cowan D, Davies B, Baker JS. Homocysteine induced cardiovascular events: a consequence of long term anabolic-androgenic steroid (AAS) abuse. Br J Sports Med. 2006 Jul;40(7):644-8. doi: 10.1136/bjsm.2005.025668. Epub 2006 Feb 17. PMID: 16488899; PMCID: PMC2564318.
38. Chen J, Rees A, Coughlan CH, Goodison W, Murphy E, Chandratheva A. Ischaemic stroke with multi-focal venous and arterial thrombosis due to hyperhomocysteinemia: anabolic androgenic steroid use and MTHFR c.667 C > T variant - a case report. BMC Neurol. 2023 Apr 26;23(1):167. doi: 10.1186/s12883-023-03197-4. PMID: 37101129; PMCID: PMC10131300.
39. Pope HG Jr, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry. 1988 Apr;145(4):487-90. doi: 10.1176/ajp.145.4.487. PMID: 3279830.
40. Venâncio DP, Tufik S, Garbuio SA, da Nóbrega AC, de Mello MT. Effects of anabolic androgenic steroids on sleep patterns of individuals practicing resistance exercise. Eur J Appl Physiol. 2008 Mar;102(5):555-60. doi: 10.1007/s00421-007-0621-6. Epub 2007 Nov 28. PMID: 18043934.
41. Thiblin I, Runeson B, Rajs J. Anabolic androgenic steroids and suicide. Ann Clin Psychiatry. 1999 Dec;11(4):223-31. doi: 10.1023/a:1022313529794. PMID: 10596737.
42. Bond P, Llewellyn W, Van Mol P. Anabolic androgenic steroid-induced hepatotoxicity. Med Hypotheses. 2016 Aug;93:150-3. doi: 10.1016/j.mehy.2016.06.004. Epub 2016 Jun 5. PMID: 27372877.
43. Neri M, Bello S, Bonsignore A, Cantatore S, Riezzo I, Turillazzi E, Fineschi V. Anabolic androgenic steroids abuse and liver toxicity. Mini Rev Med Chem. 2011 May;11(5):430-7. doi: 10.2174/138955711795445916. PMID: 21443508.
44. Alves AS, Perdigão S, Morais S, Sousa C, Salvador F. Androgenic-Anabolic Steroids: From the Gym to Drug-Induced Liver Injury. Cureus. 2022 Sep 5;14(9):e28798. doi: 10.7759/cureus.28798. PMID: 36105900; PMCID: PMC9444045.
45. Schwingel PA, Cotrim HP, Salles BR, Almeida CE, dos Santos CR Jr, Nachef B, Andrade AR, Zoppi CC. Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease. Liver Int. 2011 Mar;31(3):348-53. doi: 10.1111/j.1478-3231.2010.02346.x. Epub 2010 Oct 11. PMID: 21040407.
46. Hernandez-Nieto L, Bruguera M, Bombi J, Camacho L, Rozman C. Benign liver-cell adenoma associated with long-term administration of an androgenic-anabolic steroid (methandienone). Cancer. 1977 Oct;40(4):1761-4. doi: 10.1002/1097-0142(197710)40:4<1761::aid-cncr2820400454>3.0.co;2-c. PMID: 198105.
47. Johnson FL, Lerner KG, Siegel M, Feagler JR, Majerus PW, Hartmann JR, Thomas ED. Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet. 1972 Dec 16;2(7790):1273-6. doi: 10.1016/s0140-6736(72)92649-9. PMID: 4117807.
48. Hengge UR, Stocks K, Wiehler H, Faulkner S, Esser S, Lorenz C, Jentzen W, Hengge D, Goos M, Dudley RE, Ringham G. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. AIDS. 2003 Mar 28;17(5):699-710. doi: 10.1097/00002030-200303280-00008. PMID: 12646793.
49. Aramwit P, Kobpipat N, Satirapoj B, Kopple JD, Supasyndh O. Oxymetholone ameliorates insulin sensitivity in maintenance hemodialysis patients: a randomized controlled trial. Clin Nephrol. 2009 Apr;71(4):413-22. doi: 10.5414/cnp71413. PMID: 19356374.
50. Supasyndh O, Satirapoj B, Aramwit P, Viroonudomphol D, Chaiprasert A, Thanachatwej V, Vanichakarn S, Kopple JD. Effect of oral anabolic steroid on muscle strength and muscle growth in hemodialysis patients. Clin J Am Soc Nephrol. 2013 Feb;8(2):271-9. doi: 10.2215/CJN.00380112. Epub 2012 Nov 2. PMID: 23124786; PMCID: PMC3562853.
51. Shaha KK, Nagappan R, Badhe BA. Fatal anabolic androgenic steroid overdose in an amateur bodybuilder: a clinical and autopsy report. Forensic Sci Med Pathol. 2023 Nov 10. doi: 10.1007/s12024-023-00747-7. Epub ahead of print. PMID: 37948000.
52. Gauthier J. Effets cardiovasculaires du dopage [Cardiovascular effects of doping]. Ann Cardiol Angeiol (Paris). 2001 Sep;50(5):293-8. French. doi: 10.1016/s0003-3928(01)00032-4. PMID: 12555590.
53. Heiland CE, Schickel Y, Lehtihet M, Börjesson A, Ekström L. Supra-physiological doses of anabolic androgenic steroids impact erythropoietin and blood parameters. Drug Test Anal. 2023 Jun;15(6):599-604. doi: 10.1002/dta.3452. Epub 2023 Feb 5. PMID: 36730044.
54. Alkhunaizi AM, ElTigani MA, Rabah RS, Nasr SH. Acute bile nephropathy secondary to anabolic steroids. Clin Nephrol. 2016 Feb;85(2):121-6. doi: 10.5414/CN108696. PMID: 26587777.
55. Harrington P, Ali G, Chan A. The development of focal segmental glomerulosclerosis secondary to anabolic steroid abuse. BMJ Case Rep. 2011 Dec 2;2011:bcr0720114531. doi: 10.1136/bcr.07.2011.4531. PMID: 22669525; PMCID: PMC3233923.
56. Flachi M, Menghi V, Moschella MR, De Giovanni P, Montevecchi M, Cerretani D, Grimaldi D, Baraldi O, Fabbrizio B, La Manna G, Rigotti A. [FSGS collapsing variant during anabolic steroid abuse: Case Report]. G Ital Nefrol. 2018 Dec;35(6):2018-vol6. Italian. PMID: 30550036.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Maciej Mossakowski, Martyna Kaźmierczak, Marta Jajczak, Jakub Parys, Agnieszka Mikosińska, Patrycja Kałuziak, Aleksandra Witek, Mateusz Litwin, Stanisław Jesionek

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 102
Number of citations: 0